Federated Hermes’s SpringWorks Therapeutics SWTX Stock Holding History

Federated Hermes’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10	Closed	-$320	–	2186
2024 Q3	$320	Sell	10 -50	-83%	-$1.87K	﹤0.01%	2012
2024 Q2	$2.26K	Sell	60 -19,681	-100%	-$828K	﹤0.01%	1892
2024 Q1	$972K	Buy	+19,741	New	+$913K	﹤0.01%	1134
2022 Q4	–	Sell	-4,200	Closed	-$120K	–	2279
2022 Q3	$120K	Sell	4,200 -21	-0.5%	-$602	﹤0.01%	1596
2022 Q2	$104K	Buy	+4,221	New	+$154K	﹤0.01%	1608
2021 Q3	–	Sell	-9	Closed	-$1K	–	2309
2021 Q2	$1K	Sell	9 -35,126	-100%	-$2.67M	﹤0.01%	2158
2021 Q1	$2.58M	Sell	35,135 -27,440	-44%	-$2.15M	0.01%	1023
2020 Q4	$4.54M	Buy	+62,575	New	+$4.03M	0.01%	829

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Federated Hermes's SWTX Position: Q4 2024 in Review

Federated Hermes sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 10 shares — an estimated $320 sold.

Federated Hermes first reported a position in SWTX in Q4 2020 and held it in 8 quarters. The position peaked at $4.54M in Q4 2020. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

Federated Hermes reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
Federated Hermes sold 10 SpringWorks Therapeutics shares in Q4 2024, an estimated $320.
Federated Hermes first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 8 quarters.
Federated Hermes's SpringWorks Therapeutics position peaked at $4.54M in Q4 2020.
216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.